SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has engaged Bielderman BVBA, an experienced European contract research organization to manage the clinical process for its Barrett's esophageal cancer application under trial at certain European locations. The trial results will be used in the Company's application to the Food and Drug Administration ("FDA") for use in the United States.

 

Jim Hitchin, SpectraScience's CEO, commented, "The addition of esophageal screening to our portfolio is an important milestone for our Company and one that we think can create significant additional value for our customers. Our WavSTAT® Optical Biopsy platform can be leveraged with additional software applications, and the addition of an esophageal screening function, will allow for a greater return on hardware investment and, more importantly, can extend the level of care that physicians provide to their patients. To accelerate this process, we have engaged Bielderman to manage the data collection from European hospitals that currently have our WavSTAT Optical Biopsy System."